
Opinion|Videos|April 4, 2025
Recognizing and Understanding the Emotional Impact of Alopecia Areata
Author(s)Arash Mostaghimi, MD, MPH, Brett King, MD, PhD
A panelist discusses how alopecia areata is clinically characterized by sudden, patchy hair loss with exclamation point hairs at the periphery and is typically diagnosed through clinical examination, dermoscopy, and sometimes scalp biopsy, noting that patients with a personal or family history of autoimmune disorders, certain genetic markers, or significant stress exposure may be at higher risk for developing this condition.
Advertisement
Episodes in this series

- What are the clinical characteristics of alopecia areata, and how is alopecia areata typically diagnosed?
- Are there specific patients who might be at higher risk for developing alopecia areata?
Advertisement
Related to this article

Catch up on HCPLive’s second-half Fall Clinical 2026 coverage, from HS underdiagnosis in men and long-term acne data to advanced cutaneous SCC care.

In mice, liraglutide reduced steatosis through PPARα without needing iNKT cells, pointing to a possible GLP-1 RA plus PPARα combination.

In pooled, propensity-matched data, SC infliximab achieved week 54 endoscopic response in 65.7% of patients with ileal Crohn’s disease vs 27.1% with IV.

In ADtouch, lebrikizumab improved clearance, itch, and pain in hand and foot atopic dermatitis. Shawn Kwatra, MD, discusses what the data mean.

Phase 3 SHINE-2 data show 41.3% of children and adolescents with UC reached clinical remission after 12 weeks of mirikizumab induction.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5
